Drug
Glycerol Phenylbutyrate Ravicti
Glycerol Phenylbutyrate Ravicti: highest development phase Phase 1, developed by Horizon Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Horizon Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Glycerol Phenylbutyrate 1100 MG/ML [Ravicti] NCT04937062 | Phase 1 | STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder |
Latest
No recent events.
Follow Glycerol Phenylbutyrate Ravicti on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.